Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 14/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209801 | 0.83 | HDAC1 (0.48) | HDAC1ADORA3HDAC2KDM4ELMNA | |
| SCHEMBL2441079 | 0.82 | HDAC1 (0.47) | HDAC1ADORA3HDAC2ALDH1A1KDM4E | |
| SCHEMBL2436301 | 0.80 | HDAC1 (0.48) | HDAC1ADORA3HDAC2KDM4ELMNA | |
| SCHEMBL2210398 | 0.80 | HDAC1 (0.46) | HDAC1ADORA3HDAC2KDM4ELMNA | |
| SCHEMBL4313640 | 0.80 | HDAC1 (0.47) | HDAC1ADORA3HDAC2ALDH1A1KDM4E | |
| SCHEMBL2436499 | 0.79 | HDAC1 (0.48) | HDAC1ADORA3HDAC2KDM4ELMNA | |
| SCHEMBL13985027 | 0.79 | ADORA3 (0.51) | HDAC1ADORA3HDAC2ALDH1A1KDM4E | |
| SCHEMBL4453120 | 0.79 | HDAC1 (0.52) | HDAC1ADORA3HDAC2 | |
| SCHEMBL2210854 | 0.79 | HDAC1 (0.47) | HDAC1ADORA3HDAC2KDM4EMAPT | |
| SCHEMBL2436869 | 0.79 | CACNA1B (0.55) | HDAC1ADORA3HDAC2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009544611-A | — | — | 2009-12-17 | — | — | JP | claimed |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | claimed |
| EP-2049124-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2009-04-22 | — | — | EP | claimed |
| WO-2008010985-A2 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-7981874-B2 | Phosphorus derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981874-B2 | Phosphorus derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981874-B2 | Phosphorus derivatives as histone deacetylase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270351-A1 | PHOSPHORUS DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS | HDAC5, PPM1A, PTEN | HDAC1 4/4885ADORA3 3075/4885HDAC2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.